Shares in the pathology company jumped 6 per cent after it achieved a robust price for Lumus, which does MRI, X-rays and CT ...

OnAsset's Director of Sales. OnAsset and Phaslo's joint solutions have been deployed for over 12 months and are now scaling to support the broader market. Early successes have proven the market fit, ...

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound ...

Fulgent Genetics is transforming into a healthcare company with a focus on oncology, presenting a promising opportunity. Read ...

Healius will be in a “material net cash position’’ following the sale of its Lumus Imaging division for $965m, and will ...

We recently compiled a list of the Jim Cramer Reveals 12 Stocks Investors Should Monitor Closely. In this article, we are ...

Healthcare services provider Healius has agreed to sell its Lumus Imaging subsidiary to funds managed by Asian private equity ...

Healius is set to become debt-free after selling its radiology business, Lumus Imaging, for $965 million, exceeding analyst ...

The global anatomic pathology market was valued at approximately USD 35.17 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2032, surpassing USD ...

Healius Ltd. agreed to sell its Lumus imaging unit to a private equity group for A$965 million ($657 million), as the loss-making Australian medical diagnostics company focuses on its pathology ...

Healius shareholders were surprised on Monday about how much Affinity Equity Partners was prepared to pay for its Lumus Imaging business with the stock rallying more than 7 per cent on the news.

Katharine Mitropoulos, an author and the founder of Set Sail Press LLC, hosted a book launch event for her second book, ...